2017/05/15
SHANGHAI, May 15, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
Read more2017/03/27
SHANGHAI; BOSTON, Mass., 27 March, 2017 – LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, today announced a new collaboration with Elsevier, a world-leading provider of scientific, technical and medical information products and services.
Read more2017/03/01
Shanghai, Mar.1, 2017—WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's bioequivalence (BE) inspection with no 483 observations.
Read more2017/01/18
SHANGHAI and GAITHERSBURG, Md., Jan 18, 2016 -- WuXi AppTec, a global R&D enabling platform company, and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders—developed by their joint venture, WuXi MedImmune—has been approved by the China Food and Drug Administration (CFDA) as a class I biologic to enter Phase 1 clinical trials in China.
Read more2016/10/21
SHANGHAI, Oct. 21, 2016 --WuXi AppTec, a leading pharmaceutical, biotechnology, and medical device technology platform company, today announced that it has received the inaugural “Company of the Year” Award from BayHelix at a ceremony during the 3rd BioCentury China Healthcare Summit in Shanghai, China. The award is part of BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their achievement and contribution to the China healthcare ecosystem.
Read more